LEADER 05570nam  2200745 a 450 
001 9910778703803321
005 20230331015407.0
010   $a1-280-21225-X
010   $a9786610212255
010   $a0-309-54356-8
010   $a0-585-12524-4
035   $a(CKB)111004366659530
035   $a(EBL)3376920
035   $a(SSID)ssj0000204431
035   $a(PQKBManifestationID)11954473
035   $a(PQKBTitleCode)TC0000204431
035   $a(PQKBWorkID)10174978
035   $a(PQKB)10716050
035   $a(MiAaPQ)EBC3376920
035   $a(Au-PeEL)EBL3376920
035   $a(CaPaEBR)ebr10062761
035   $a(CaONFJC)MIL21225
035   $a(OCoLC)923266968
035   $a(EXLCZ)99111004366659530
100   $a19900501d1990      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aModern methods of clinical investigation$b[electronic resource] /$fAnnetine C. Gelijns, editor ; Committee on Technological Innovation in Medicine, Institute of Medicine
210   $aWashington, D.C. $cNational Academy Press$d1990
215   $a1 online resource (244 p.)
225 1 $aMedical innovation at the crossroads ;$vv. 1
300   $aProceedings of a workshop held on May 3-4, 1989, supported by the Howard Hughes Medical Institute and the National Center for Health Services Research of the Department of Health and Human Services (grant 5 RO9 HS055 26 02).
300   $aIncludes index.
311   $a0-309-04286-0 
320   $aIncludes bibliographical references.
327   $a""Modern Methods of Clinical Investigation""; ""Copyright""; ""Acknowledgments""; ""Preface""; ""Contents""; ""List of Abbreviations""; ""1 Medical Technology Development: An Introduction to the Innovation-Evaluation Nexus ""; ""PUTTING CLINICAL EVALUATION IN CONTEXT""; ""ISSUES IN INNOVATION AND EVALUATION: THE CASE OF STABLE ANGINA PECTORIS""; ""Beta-Blockers""; ""Coronary Artery Bypass Grafting""; ""PTCA Catheter Equipment""; ""Evaluative Shortcomings in Technology Development""; ""IMPROVING THE INNOVATION-EVALUATION NEXUS""; ""The Selection of Endpoints in Evaluative Research""
327   $a""The Selection of Methods for Clinical Investigation""""Policy Mechanisms for Improving Developmental Decision Making""; ""REFERENCES""; ""2 The Selection of Endpoints in Evaluative Research ""; ""SURROGATE VERSUS CLINICAL ENDPOINTS""; ""CLINICAL ENDPOINTS""; ""SURROGATE ENDPOINTS""; ""REFERENCES""; ""3 Advances in Health Status Measurement: The Potential to Improve Experimental and Non-Experimental Data Collection""; ""THE CONDUCT OF CLINICAL TRIALS""; ""MEASUREMENT OF QUALITY OF LIFE AND OF HEALTH STATUS""; ""INCLUSION OF QUALITY OF LIFE AND HEALTH STATUS MEASURES IN CLINICAL TRIALS""
327   $a""FOUR PROBLEMS REGARDING THE MEASUREMENT OF HEALTH STATUS IN CLINICAL TRIALS""""REFERENCES""; ""4 What Is Outcomes Research? ""; ""WHICH RATE IS RIGHT?""; ""ENGAGING PATIENTS IN THE DECISION PROCESS""; ""EXTENDING ASSESSMENT TO ALL RELEVANT TREATMENT THEORIES""; ""THE EVALUATIVE CLINICAL SCIENCES AND THE FUTURE OF MEDICINE""; ""REFERENCES""; ""5 Strengths and Weaknesses of Health Insurance Data Systems for Assessing Outcomes""; ""STRENGTHS""; ""System-Wide, Population-Based Data""; ""Efficacy versus Effectiveness""; ""Large Numbers and Time Series""; ""Events Unaffected by Recall""
327   $a""Unobtrusive Nature""""Multiple Comparisons""; ""Design Flexibility""; ""Potential for Multiple Projects""; ""Focus on Risks""; ""Clinical Decision Making""; ""WEAKNESSES""; ""Structural Limitations""; ""Bias Due to Reporting and Coding""; ""Bias Due to Differential Contact""; ""Benefits of Treatment""; ""CONTROVERSIAL AREAS""; ""Risk Adjustment""; ""Outcome Measures""; ""EXPANDING DATA BASES""; ""Record Linkage""; ""Primary Data Collection""; ""DISCUSSION""; ""REFERENCES""; ""6 Prescription-Event Monitoring: An Example of Total Population Post-Marketing Drug Surveillance ""
327   $a""""THE NUMBERS GAME""""""VOLUNTARY REPORTING SYSTEMS""; ""POST-MARKETING SURVEILLANCE""; ""PRESCRIPTION-EVENT MONITORING""; ""COMPARATIVE STUDIES OF NSAIDS""; ""POST-MARKETING SURVEILLANCE AND POST-MARKETING CLINICAL TRIALS""; ""CONCLUSION""; ""REFERENCES""; ""7 The Role of Decision Analysis in the Translation of Research Findings into Clinical Practice ""; ""DECISION ANALYSIS AT THE INTERFACE BETWEEN CLINICAL INVESTIGATION AND CLINICAL PRACTICE""; ""WHAT DECISION ANALYSIS IS""; ""THE LIMITATIONS OF DECISION ANALYSIS: WHAT IT IS NOT""
327   $a""SETTING PRIORITIES AND PARAMETERS FOR CLINICAL INVESTIGATION""
410  0$aMedical innovation at the crossroads ;$vv. 1.
606   $aMedical technology$xEvaluation$vCongresses
606   $aMedical innovations$xEvaluation$vCongresses
606   $aMedical care$xTechnological innovations$vCongresses
606   $aMeta-analysis$vCongresses
615  0$aMedical technology$xEvaluation
615  0$aMedical innovations$xEvaluation
615  0$aMedical care$xTechnological innovations
615  0$aMeta-analysis
676   $a610/.72
701   $aGelijns$b Annetine$01528675
712 02$aInstitute of Medicine (U.S.).$bCommittee on Technological Innovation in Medicine.
712 02$aHoward Hughes Medical Institute.
712 02$aNational Center for Health Services Research.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910778703803321
996   $aModern methods of clinical investigation$93845350
997   $aUNINA